Equities

Implanet SA

Implanet SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)0.073
  • Today's Change0.002 / 3.11%
  • Shares traded39.27k
  • 1 Year change-57.31%
  • Beta0.9578
Data delayed at least 15 minutes, as of May 03 2024 13:47 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Implanet SA is a France-based medical technology company. It is involved in the design, production and marketing of medical equipment, such as medical implants and devices used in orthopedic surgery. The Company's products include prosthetic knees, spinal bracing systems, intersomatic cages, pins, suture threads, screws, and anchors, among others. Its activities, and flagship products, include JAZZ (Spine System) and MADISON (Knee implant). JAZZ implant is designed to improve the treatment of spinal pathologies requiring vertebral fusion surgery. MADISON implant is designed for first-line prosthetic knee surgery.

  • Revenue in EUR (TTM)7.45m
  • Net income in EUR-6.68m
  • Incorporated2006
  • Employees41.00
  • Location
    Implanet SATechnopole Bordeaux MontesquieuAllee Francois MagendieMARTILLAC 33650FranceFRA
  • Phone+33 557995555
  • Fax+33 557995700
  • Websitehttps://www.implanet.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Implanet SA7.45m-6.68m9.12m41.00------1.23-0.1704-0.17040.1933-0.00420.59310.90834.19182,973.00-53.17-37.44-159.90-86.7456.8359.59-89.65-67.430.2932-24.761.03---7.242.08-88.59---2.20--
Spineguard SA4.31m-4.18m11.04m24.00--1.83--2.56-0.1084-0.10840.11180.12700.38271.284.68179,700.00-37.12-23.69-52.43-42.7372.8975.60-97.00-45.021.73-13.510.3384---22.98-10.65-74.81--89.42--
Laboratoires Euromedis SA49.54m-5.51m13.66m194.00--0.4896--0.2756-1.84-1.8416.469.700.82833.544.88255,371.10-9.19---11.45--32.67---11.09--3.57-12.830.2875---51.58---362.99------
Theraclion SA1.87m-4.88m16.92m30.00--2.50--9.05-0.1362-0.13620.05040.14810.10210.2821.2366,785.00-26.65-40.08-35.36-59.9654.2152.19-260.94-276.132.50-56.170.2546---16.58-12.66-32.02--11.77--
Alpha Mos SA6.16m-3.39m17.57m48.00------2.85-0.3105-0.31050.5637-0.50660.84242.244.99128,270.80-46.70-50.01-481.38-102.4971.2768.37-55.43-74.150.4423-10.7611.30--2.257.46-39.13--7.59--
Diagnostic Medical Systems SA42.15m-9.76m18.07m147.00--1.46--0.4288-0.4982-0.24812.230.70230.80271.816.81286,755.10-18.73-12.33-33.53-22.1437.5837.72-23.33-16.450.7105-3.520.5938--19.5111.62-106.30------
Mauna Kea Technologies SA10.90m-2.17m24.64m67.00----22.902.26-0.0488-0.04880.2449-0.33860.52652.016.73194,696.40-2.61-58.19-5.19-83.9137.11-1.33-4.96-182.400.740529.852.22---2.872.2616.85---27.66--
Data as of May 03 2024. Currency figures normalised to Implanet SA's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.